Insmed Q2 Revenue Soars 49% on BRINSUPRI Launch, Guidance Raised
INSM sits 31% above its 52-week low of $90.39.
Summary
Insmed delivered a massive Q2 beat with revenue of $425.5M, well above the $392.84M consensus, driven by a 49% sequential jump in BRINSUPRI sales. Net loss narrowed dramatically to $13.2M from $321.7M a year ago, signaling a rapid path to profitability. Management raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted the peak revenue estimate for its three lead programs to over $14B. This follows the positive 12-month TPIP data in July and the shelf filing in May, but today's numbers materially reset the growth trajectory. The stock closed at $99.02 yesterday, leaving significant room versus the $198 analyst median target.
At the time of this announcement, INSM was trading at $118.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.